Associated Papers
A targeted next-generation sequencing panel for identification of clinically relevant mutation profiles in solid tumours.
Das K et al.
Scientific Reports, 2025
Targeted therapy guided by circulating tumor DNA analysis in advanced gastrointestinal tumors.
Nakamura Y et al.
Nature Medicine, 2025
Base editing screens define the genetic landscape of cancer drug resistance mechanisms.
Coelho MA et al.
Nature Genetics, 2024
Whole-Exome Sequencing Reveals Novel Candidate Driver Mutations and Potential Druggable Mutations in Patients with High-Risk Neuroblastoma.
Nokchan N et al.
Journal of Personalized Medicine, 2024
Targeting lung cancer with clinically relevant EGFR mutations using anti-EGFR RNA aptamer.
Thomas BJ et al.
Molecular Therapy. Nucleic Acids, 2023
Circulating tumor DNA landscape and prognostic impact of acquired resistance to targeted therapies in cancer patients: a national center for precision medicine (PRISM) study.
Bayle A et al.
Molecular Cancer, 2023
Panitumumab Plus Trifluridine-Tipiracil as Anti-Epidermal Growth Factor Receptor Rechallenge Therapy for Refractory RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial.
Napolitano S et al.
Jama Oncology, 2023
Detection of Glioma-Related Hotspot Mutations Through Sequencing of Cerebrospinal Fluid (CSF)-Derived Circulating Tumor DNA: A Pilot Study on CSF-Based Liquid Biopsy for Primary Spinal Cord Astrocytoma.
Cheng L et al.
Neurospine, 2023
Metastatic Colorectal Cancer Treatment Response Evaluation by Ultra-Deep Sequencing of Cell-Free DNA and Matched White Blood Cells.
van 't Erve I et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2023
Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial.
Sartore-Bianchi A et al.
Nature Medicine, 2022
Next-Generation Sequencing on Circulating Tumor DNA in Advanced Solid Cancer: Swiss Army Knife for the Molecular Tumor Board? A Review of the Literature Focused on FDA Approved Test.
Vasseur D et al.
Cells, 2022
Comprehensive germline and somatic genomic profiles of Chinese patients with biliary tract cancer.
Yu H et al.
Frontiers in Oncology, 2022
Analysis of single-nucleotide polymorphisms in genes associated with triple-negative breast cancer.
G V et al.
Frontiers in Genetics, 2022
Evaluation of the Idylla ctEGFR mutation assay to detect EGFR mutations in plasma from patients with non-small cell lung cancers.
Gilson P et al.
Scientific Reports, 2021
Frequency of S492R mutations in the epidermal growth factor receptor: analysis of plasma DNA from patients with metastatic colorectal cancer treated with panitumumab or cetuximab monotherapy.
Price T et al.
Cancer Biology & Therapy, 2020
Clinical impact of a cancer genomic profiling test using an in-house comprehensive targeted sequencing system.
Hayashi H et al.
Cancer Science, 2020
Spectrum of driver mutations and clinical impact of circulating tumor DNA analysis in non-small cell lung cancer: Analysis of over 8000 cases.
Mack PC et al.
Cancer, 2020
ctDNA analysis reveals different molecular patterns upon disease progression in patients treated with osimertinib.
Romero A et al.
Translational Lung Cancer Research, 2020
Pharmacogenomics, biomarker network, and allele frequencies in colorectal cancer.
López-Cortés A et al.
The Pharmacogenomics Journal, 2020
RAS and BRAF mutations in cell-free DNA are predictive for outcome of cetuximab monotherapy in patients with tissue-tested RAS wild-type advanced colorectal cancer.
van Helden EJ et al.
Molecular Oncology, 2019
IKKα Kinase Regulates the DNA Damage Response and Drives Chemo-resistance in Cancer.
Colomer C et al.
Molecular Cell, 2019
Genotyping of Circulating Tumor DNA Reveals the Clinically Actionable Mutation Landscape of Advanced Colorectal Cancer.
Cao W et al.
Molecular Cancer Therapeutics, 2019
Unstable Genome and Transcriptome Dynamics during Tumor Metastasis Contribute to Therapeutic Heterogeneity in Colorectal Cancers.
Cho SY et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2019
Nanobody Targeting of Epidermal Growth Factor Receptor (EGFR) Ectodomain Variants Overcomes Resistance to Therapeutic EGFR Antibodies.
Tintelnot J et al.
Molecular Cancer Therapeutics, 2019
Plasma Dynamics of RAS/RAF Mutations in Patients With Metastatic Colorectal Cancer Receiving Chemotherapy and Anti-EGFR Treatment.
Thomsen CB et al.
Clinical Colorectal Cancer, 2019
Detection of ERBB2 (HER2) Gene Amplification Events in Cell-Free DNA and Response to Anti-HER2 Agents in a Large Asian Cancer Patient Cohort.
Lee J et al.
Frontiers in Oncology, 2019
Clinical Utility of Analyzing Circulating Tumor DNA in Patients with Metastatic Colorectal Cancer.
Nakamura Y et al.
The Oncologist, 2018
Integrative omics analyses broaden treatment targets in human cancer.
Sengupta S et al.
Genome Medicine, 2018
Genomic Landscape of Cell-Free DNA in Patients with Colorectal Cancer.
Strickler JH et al.
Cancer Discovery, 2018
Cell-Free DNA Profiling to Discover Mechanisms of Exceptional Response to Cabozantinib Plus Panitumumab in a Patient With Treatment Refractory Metastatic Colorectal Cancer.
Jia J et al.
Frontiers in Oncology, 2018
Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer.
Van Emburgh BO et al.
Nature Communications, 2016
Liquid biopsy monitoring uncovers acquired RAS-mediated resistance to cetuximab in a substantial proportion of patients with head and neck squamous cell carcinoma.
Braig F et al.
Oncotarget, 2016
The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer.
Sánchez-Martín FJ et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2016
MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations.
Arena S et al.
Science Translational Medicine, 2016
Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer.
Arena S et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2015
ErbB polymorphisms: insights and implications for response to targeted cancer therapeutics.
Alaoui-Jamali MA et al.
Frontiers in Genetics, 2015
Clonal architectures and driver mutations in metastatic melanomas.
Ding L et al.
Plos One, 2014
The Panitumumab EGFR Complex Reveals a Binding Mechanism That Overcomes Cetuximab Induced Resistance.
Sickmier EA et al.
Plos One, 0
Plasticity of Resistance and Sensitivity to Anti-Epidermal Growth Factor Receptor Inhibitors in Metastatic Colorectal Cancer.
Sartore-Bianchi A et al.
Handbook of Experimental Pharmacology, 0